Publicly traded R&D partnership Almada Ventures reported today (Monday) another full exit. Portfolio company TailorMed, which operates in digital health, completed a merger transaction under which New York-based private equity firm GrowthCurve Capital became its controlling shareholder.

As part of the move, Almada is selling its entire stake in the company for gross cash proceeds of about $7.6 million.
A 3.15x multiple on the investment
Immediately before the transaction was completed, Almada held about 3.05% of TailorMed's share capital on a fully diluted basis. Against a cumulative investment cost of about $2.42 million, the current proceeds reflect a multiple of about 3.15x on the money and are expected to generate a gross profit of about $5 million for the partnership before taxes and expenses.

The value of the stake on the partnership's books stood at just about $3.97 million at the end of June 2026, meaning the proceeds achieved in the transaction are significantly higher than the book value.
Record year for exits and cash distributions
The current transaction caps a series of successful exits for Almada during 2026.
Earlier this year, the partnership completed the sale of BioProtect to medical device giant Olympus in a $270 million transaction that generated a profit of about $8 million for Almada, alongside a profitable partial exit from Clanz Technologies.

This series of exits enabled Almada to reach $12 million in approved distributions to investors over the course of the year, including capital reductions and dividends, placing the partnership in the top decile for cash returns relative to 2020-vintage funds, according to benchmark data from Carta.
Accelerating artificial intelligence technologies in medicine
TailorMed develops technology solutions for health care providers, pharmacies and patients, aimed at easing the financial burden associated with medical treatments.

GrowthCurve Capital's entry as controlling shareholder is intended to accelerate the expansion of TailorMed's operations and support the continued development of artificial intelligence-based solutions for the U.S. and global health care markets.











